Shaperon seeks 카지노 바카라 partners for NuGel and NuDifin at J.P. Morgan Healthcare Conference

[by Ji, Yong Jun] Shaperon announced on January 7 that it will participate in the 44th JP Morgan Healthcare Conference (JPM), to be held in San Francisco from January 12 to 15 (local time). In parallel, the company will take part in ‘Global IR @ JPM 2026,’ where it plans to present its clinical development progress and commercialization strategy to global investors, with a particular emphasis on ‘NuGel,’ an atopic dermatitis treatment candidate, and ‘NuDifin,’ a diabetic foot ulcer treatment candidate.

‘Global IR @ JPM 2026’ is a global investor relations (IR) program co-hosted by Korea Biotechnology Industry Organization (KoreaBio), the U.S.-based law firm Sidley Austin LLP, and the U.S. biopharmaceutical journal BioCentury in conjunction with the JP Morgan Healthcare Conference, the world's largest biotechnology investment forum. This investment-oriented event brings together global pharmaceutical companies, financial institutions, legal experts, and media representatives and is widely regarded as a key platform for in-depth discussions on potential collaboration opportunities with companies advancing promising clinical-stage pipelines.

As the clinical performance and technological competitiveness of Korean biopharmaceutical companies have increasingly drawn 카지노 바카라 attention, interest from multinational pharmaceutical firms and international investors has likewise intensified. Reflecting this trend, major 카지노 바카라 pharmaceutical companies, including Johnson & Johnson (J&J) and Pfizer, are scheduled to participate as investment panelists at the event, where they will explore potential collaboration opportunities with companies developing promising pipelines.

At the event, Shaperon will conduct an investor relations (IR) presentation targeting 카지노 바카라 pharmaceutical companies and international investment banks (IBs), outlining its mid- to long-term growth strategy with a particular focus on its core pipeline of novel drugs targeting the inflammasome complex, a key driver of future growth. In addition, the company plans to engage in follow-up meetings with multinational pharmaceutical partners and 카지노 바카라 investment institutions.

‘NuGel,’ one of the core pipeline assets targeting GPCR19 for inflammatory complex inhibition, is a topical treatment candidate for atopic dermatitis. Phase 2b clinical trials are currently being conducted in both the United States and Korea. NuGel's key differentiation lies in its unique mechanism of action, which simultaneously regulates inflammatory signaling across the initial to the amplification phases of the inflammatory response.

NuDifin, a candidate for the treatment of diabetic foot ulcers, has successfully completed Phase 1 clinical trials and is currently in development for this indication. The candidate is designed to exert dual therapeutic effects by concurrently suppressing pathological inflammatory responses and improving the tissue regeneration environment required for effective wound healing. Diabetic foot ulcers remain a particularly difficult-to-treat condition due to complications like peripheral neuropathy and impaired blood circulation, and there is a marked lack of effective drug treatment options in clinical practice.

"We anticipate completing the U.S. Phase 2b clinical trials in H1 2026, and the underlying technology is protected by patents. At the Global IR @ JPM 2026, we intend to present NuGel's clinical performance and its competitive differentiation, which is based on its GPCR19-targeted design and favorable safety profile, distinguishing it from existing treatments. Through this event, we aim to broaden engagement with global pharmaceutical companies and financial institutions and initiate full-scale discussions on the technological value and commercialization potential of our core pipeline, including NuGel. These efforts are expected to further advance and concretize our global partnership initiatives," a Shaperon official stated.